What tariff reductions apply to Indian pharma exports to the EU?

The FTA eliminates tariffs of up to 11% on pharmaceutical products. India already supplies approximately 40% of EU generic medicines, and the FTA makes this trade even more cost-effective.

What regulatory approvals are needed to export pharma to Europe?

Indian pharma manufacturers need EMA (European Medicines Agency) marketing authorization or national authorizations, GMP certification from EU inspectorates, and compliance with EU Falsified Medicines Directive requirements.

Where are India's major pharmaceutical manufacturing centers?

Hyderabad (bulk drugs and APIs), Mumbai (formulations), Ahmedabad (generics), Baddi/Himachal Pradesh (formulations), and Sikkim (formulations with tax advantages) are the primary pharma hubs.

Pharmaceuticals & Healthcare

Tariffs up to 11% eliminated — India already supplies 40% of EU generic medicines

India is the world's largest supplier of generic medicines by volume and already provides roughly 40% of the generic drugs consumed across the European Union. The bilateral pharmaceuticals trade between India and the EU stands at approximately €8.2 billion, growing at a compound rate of 9.4% annually. Indian manufacturers hold over 700 active EU GMP certificates, and the top five — Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo — each generate €500M+ in European revenue. On the European side, major innovator firms (Bayer, Sanofi, Novartis, GSK) maintain active supply and licensing relationships with Indian CDMO and API producers, making this corridor genuinely bi-directional.

The India-EU Free Trade Agreement eliminates tariffs of up to 11% on finished dosage forms, active pharmaceutical ingredients (APIs), medical devices, and diagnostic reagents. For Indian exporters, this closes the residual cost gap against Chinese API suppliers and Southeast Asian finished-form competitors. For European buyers — hospital groups, pharmacy chains, and parallel importers — it means lower procurement costs on a product category where every basis point matters given reference-pricing regimes across the EU.

Key production clusters on the Indian side include Hyderabad (Genome Valley — bulk drugs and biotech), Mumbai (formulation headquarters for most top-10 firms), Ahmedabad (injectables and ophthalmic specialties), Baddi in Himachal Pradesh (oral solid dosage forms with tax incentives), and Sikkim (export-oriented units with GST advantages). On the European side, Germany, France, Italy, the Netherlands, Spain, and Belgium each represent distinct regulatory environments, reimbursement systems, and market-entry strategies that exporters must navigate individually.